#IACH2024

To update you on the exciting content presented at the 7th Annual Meeting of the International Academy for Clinical Hematology (IACH), we have collated our social media coverage. Catch up with our posts relating to MPN below.

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Alberto Alvarez-Larrán, @hospitalclinic shares insights on patients with high-risk PV.
They provide an overview of potential high-risk prognostic factors in this patient population.
Follow our live feed for more updates:… pic.twitter.com/vaGEzqI4ep

— MPN_Hub (@MPN_Hub) September 21, 2024

CONGRESS | @TheIACH #IACH2024 | POSTER@nesrinebensaye1, Farhat Hached University Hospital, presents a case series of 3 male patients (median age: 73 years) with #PolycythemiaVera intolerant/resistant to hydroxycarbamide.
Treatment with ruxolitinib was well tolerated and resulted… pic.twitter.com/FFLkMkO2dH

— MPN_Hub (@MPN_Hub) September 21, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Adam Mead @AdamMead_Oxford @UniofOxford discusses when, how, and why JAK2V617F VAF assessment should be incorporated into the management of patients with PV.
They highlight results from clinical studies and provide some practical… pic.twitter.com/R1lD9lZk3h

— MPN_Hub (@MPN_Hub) September 21, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Deepti Radia @DeeptiRadia @G_ICEMD provides an overview of systemic mastocytosis and the current treatment landscape.
They discuss treatment options, including tyrosine kinase inhibitors, allo-HSCT, and potential novel combination… pic.twitter.com/fGIqpyfavN

— MPN_Hub (@MPN_Hub) September 20, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Ruben Mesa @mpdrc @LevineCancer @AtriumHealthWFB provides an update on early/pre-fibrotic myelofibrosis.
They raise the need to differentiate between early and pre-fibrotic myelofibrosis, and discuss the potential role of treatment… pic.twitter.com/gC9xkujplu

— MPN_Hub (@MPN_Hub) September 20, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Shahram Kordasti @Skordasti @KingsCollegeLon discusses inflammation in patients with MPN.
They highlight the effects of prolonged inflammation on the immune system and bone marrow microenvironment, and novel approaches to control… pic.twitter.com/iOFDPdKnJp

— MPN_Hub (@MPN_Hub) September 20, 2024

CONGRESS | @TheIACH #IACH2024 | POSTER@nesrinebensaye1, Farhat Hached University Hospital, presents a case of a female patient with hydroxycarbamide-resistant ET. Treatment with ruxolitinib resulted in a favorable hematological response and reduction in spleen size at a median… pic.twitter.com/df79uB8aWr

— MPN_Hub (@MPN_Hub) September 20, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Claire Harrison @harrisoncn1, @GSTTnhs, presents updates on treatment of high-risk essential thrombocytosis, highlighting novel therapeutic approaches such as pelabresib (BET inhibitor), bomedemstat (LSD1 inhibitor), calreticulin… pic.twitter.com/KEc4lsp1E6

— MPN_Hub (@MPN_Hub) September 20, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Claire Woodley @WoodleyClaire, @GSTTnhs, shares insights on management of fatigue in patients with #MPN. They discuss the physical, cognitive, and emotional domains of fatigue, various causes and compounding factors, and the role of… pic.twitter.com/pQumsSe9Rj

— MPN_Hub (@MPN_Hub) September 20, 2024

CONGRESS | @TheIACH #IACH2024 | POSTER
Moazzam Shahzad, @MoffittNews, discusses factors predicting allo-HCT outcomes in patients aged >70 years with #myelofibrosis (N=51). 2-year OS was 58.8%. Hispanic ethnicity and use of mismatched unrelated donors were associated with… pic.twitter.com/ESpWRNpGKH

— MPN_Hub (@MPN_Hub) September 20, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Arnon Nagler @nagler_EBMT, @TelAvivUni, presents a global perspective on transplantation for #myelofibrosis, highlighting that HSCT is the only curative option available, despite the emergence of novel therapies. While… pic.twitter.com/tns2PFjbNX

— MPN_Hub (@MPN_Hub) September 19, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION@TaniaJain11, @HopkinsMedicine, shares insights on transplantation in #myelofibrosis from a US perspective, highlighting that timely consideration is important and that searching for a fully matched donor should not cause delays.… pic.twitter.com/QnQ0iI8SYf

— MPN_Hub (@MPN_Hub) September 19, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION@FlorianHeidel, @MHH_life, debates that combination therapies are not currently feasible for #myelofibrosis, stating that while spleen volume responses were improved in the MANIFEST-2 and TRANSFORM-1 studies, there were concerns… pic.twitter.com/CQYxqLe9cW

— MPN_Hub (@MPN_Hub) September 19, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION@AdamMead_Oxford, @UniofOxford debates in favor of using combination therapies for #myelofibrosis, considering that achieving meaningful disease modification is challenging with single-agent JAK inhibitors. He cites evidence from phase… pic.twitter.com/kQ7IvyF9pt

— MPN_Hub (@MPN_Hub) September 19, 2024

CONGRESS | @TheIACH #IACH2024 | PRESENTATION
Naveen Pemmaraju @doctorpemm, @MDAndersonNews, provides an overview of JAK inhibitors in the treatment of #myelofibrosis, highlighting the exciting landscape with four approved therapies: ruxolitinib, fedratinib, pacritinib, and… pic.twitter.com/SG1jjiKYrm

— MPN_Hub (@MPN_Hub) September 19, 2024